Kornimate/medical-research-clean huggingface dataset:
a comparison of the accuracy of toric intraocular lens formulas

Conditions: Astigmatism

Summary: to compare the accuracy of the abulafia-koch, the barrett, the barrett post ,the evo , the new holladay with total surgical-induced astigmatism, the kane and and the næser-savini toric intraocular lens (iol) power formulas using a large database of toric iol refractive outcomes

to compare the accuracy of the abulafia-koch, the barrett, the barrett post ,the evo , the new holladay with total surgical-induced astigmatism, the kane and and the næser-savini toric intraocular lens (iol) power formulas using a large database of toric iol refractive outcomes.retrospective consecutive case series.one hundred seventy-two eyes of 172 patients who had a toric iol inserted during surgery.one eligible eye from patients having uncomplicated cataract surgery with insertion of an alcon sn6at(2-9) iol (alcon laboratories, inc, fort worth, tx) from 1 surgeon were included in the study. pre-operative were measured using either the iolmaster 500 or 700 (carl zeiss meditec ag, jena, germany). using vector calculation, the predicted postoperative refractive astigmatism was calculated for each formula. this was compared with the actual postoperative refractive astigmatism to give the prediction error.

Eligibility criteria:
inclusion criteria: * uncomplicated cataract surgery with a temporal clear corneal incision,with preoperative biometry using either the iolmaster 500 (softwareversions 5.5 and 7.7) or 700 (software version 1.50; carl zeiss meditec ag, jena, germany) * subjective manifest refraction performed by any of the orthoptists in the practice and measurement of the actual postoperative axis of the iol alignment performed in the same visit an average of 1 or 3months after surgery. exclusion criteria: * any corneal disease (keratoconus, other ectasia, pterygium, or previous trauma); * previous ophthalmic operations, including laser vision correction, vitrectomy, pterygium surgery, penetrating glaucoma surgery, or scleral buckling procedures * intraoperative or postoperative complications * postoperative corrected distance visual acuity worse than 6/9

Keywords: calculators cataract intraocular lens power toric
timing of planned caesarean section and morbidity of the newborn

Conditions: Respiratory Disorders; Intensive Care, Neonatal

Summary: the caesarean section rate is rising globally. about 10% of the newborns are submitted to a neonatal department after planned caesarean section, primarily with respiratory disorders. more children are submitted if caesarean is performed earlier in pregnancy. study hypothesis: more newborns are admitted after planned caesarean at 38 weeks and 3 days of gestation than after 39 weeks and 3 days of gestation. aim of study: to compare elective caesarean section performed at 38 weeks and 3 days of gestation with 39 weeks and 3 days of gestation. according to this timing to determine the proportion of newborns admitted within 48 hours after birth.


Eligibility criteria:
inclusion criteria: * elective caesarean section * gestational age determined at 12 weeks ultrasound scan * singleton pregnancy exclusion criteria: * \< 18 years of age (at time of randomization) * in need of an interpreter to communicate in danish * diabetes, both gestational and before pregnancy * a mother with an estimated high risk of caesarean section before 39+5 weeks

Keywords: neonatal admission elective caesarean section timing choice behavior intraoperative complications postoperative complications
evaluating dashboard-integrated pharmacist-led education on improving sacubitril/valsartan adherence in heart failure (pharmd assist hfref)

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF); Sacubitril/Valsartan; Medication Adherence

Summary: the goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed sacubitril/valsartan. the main question it aims to answer is: can pharmacist-led interactive visualization dashboards improve adherence to sacubitril/valsartan compared to usual care without the dashboard intervention? researchers will compare patients receiving pharmacist-led education with interactive dashboards to those receiving standard education, assessing differences in medication adherence and clinical outcomes, among others. participants will: * complete baseline and follow-up questionnaires on medication adherence and satisfaction with pharmacist-provided services, and others. * engage in education sessions led by pharmacists, with or without dashboard integration. the study outcomes will include medication adherence, and secondary outcomes such as patient satisfaction with pharmacist-provided services, optimized guideline-directed medical therapy score, time to high medication adherence, the calculated proportion of days covered, new york heart association functional classification, and the net promoter score used for evaluating recommendation and satisfaction with the dashboard intervention.


Eligibility criteria:
inclusion criteria: * adults aged 20 or older * a diagnosis of hfref, which is defined by a left ventricular ejection fraction of 40% or less * currently receiving sacubitril/valsartan at the time of recruitment * receiving care at the cardiology department or cardiology ward at national taiwan university hospital * referral from the clinicians at national taiwan university hospital exclusion criteria: * unable or unwilling to provide informed consent, adhere to study protocols, or complete required questionnaires in person during three scheduled visits (i.e., 3, 6, 12 months after the baseline measurement) * having received care at the pharmacist-led hf clinic at national taiwan university hospital

Keywords: heart failure with reduced ejection fraction medication adherence dashboard health information technology patient education pharmacist pragmatic trial randomized controlled trial sacubitril/valsartan implementation
safety study of totally laparoscopic resection with natural orifice specimen extraction (nose) for rectosigmoid cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to compare the safety and efficacy of laparoscopic resection with natural orifice specimen extraction versus conventional laparoscopic surgery for sigmoid colon or rectal cancer.

further study details as provided by chinese academy of medical sciences.

Eligibility criteria:
inclusion criteria: * 18 years \< age \< 80 years * tumor located in rectosigmoid (defined as 8- to 30-cm from the anal verge) * pathological rectosigmoid adenocarcinoma * preoperative t stage ranging from t1 to t4a according to the 7th edition of american joint committee on cancer (ajcc) staging manual * tumor size of 6 cm or less; * eastern cooperative oncology group (ecog) score is 0-1 * american society of anesthesiology (asa) score is ⅰ-ⅲ * informed consent exclusion criteria: * body mass index (bmi) \>30 kg/m2 * pregnant woman or lactating woman * severe mental disease * previous abdominal surgery * emergency operation due to complication (bleeding, perforation or obstruction) caused by colorectal cancer * requirement of simultaneous surgery for other disease

Keywords: colorectal cancer laparoscopic surgery natural orifice specimen extraction inflammatory response
safety, tolerability, pharmacokinetics (pk) of the anti-orthopox drug, st-246

Conditions: Orthopoxviral Disease

Summary: the purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, st-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. the results of this trial determine which dose will be used in expanded pivotal safety trials.

this study is a phase ii, double-blind, randomized, placebo-controlled, multi-center (3 sites) trial to assess the safety, tolerability, and pharmacokinetics of 400 mg and 600 mg form i st-246 when administered as a single daily oral dose for 14 days to 107 healthy, fed volunteers between 18 and 74 years of age. safety parameters included adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, and urinalysis) and electrocardiograms.

Eligibility criteria:
inclusion criteria: 1. 18 - 75 yrs 2. healthy volunteer 3. ability to consent 4. available for clinical follow-up for study 5. not taking other medications 6. adequate venous access 7. using adequate birth control; negative pregnancy test 8. able and willing to avoid alcohol for screening and study duration exclusion criteria: 1. inability to swallow study medication 2. pregnant or breast-feeding 3. medical condition, e.g., asthma, hypertension, angioedema, traumatic brain injury other than concussion, bleeding disorder, blood dyscrasia, idiopathic seizures, cardiac disease that limits activity, diabetes, active malignancy, hepatitis b or c, hiv or aids, chronic microbial infection, 4. history of drug allergy that contraindicates study participation 5. medical, psychiatric, social, occupational or other reason that jeopardizes the safety/rights of participant or renders he/she unable to comply with the protocol (including drug or alcohol abuse, or homelessness) 6. clinically abnormal ecg 7. has or will participate in a clinical trial or experimental treatment within 30 days of, or during, the study 8. cannot or will not do physical exercise 24 hrs before and after pk days 9. will not consume grapefruit/grapefruit juice during study 10. vaccination within 2 wks of screening, or planned before day 42 of study 11. treatment with prednisone or equivalent immunosuppressant/modulatory drug \<3 mths before screening 12. clinically significant physical exam and lab results \<2weeks from 1st study drug dose

Keywords: orthopoxvirus smallpox this is a safety study only st-246 is being studied for treatment of orthopoxviruses
saxagliptin compared to glimepiride in elderly type 2 diabetes patients, with inadequate glycemic control on metformin

Conditions: Type 2 Diabetes Mellitus

Summary: this study will evaluate the efficacy and tolerability of saxagliptin compared to glimepiride in elderly patients with type 2 diabetes mellitus who have inadequate glycaemic control on metformin monotherapy.


Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * established clinical diagnosis of type 2 diabetes. treatment with a stable metformin monotherapy, for at least 8 weeks prior to visit 1 * hba1c ≥7.0% and ≤9.0% exclusion criteria: * type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma. current use of any injectable or oral antihyperglycemic agent excluding metformin. * renal impairment as defined by a creatinine clearance \<60 ml/min * individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study

Keywords: type 2 diabetes mellitus elderly patients saxagliptin randomised double-blind
nanofuse® pl gutter pmcf

Conditions: Degenerative Disc Disease

Summary: this study is a post market follow up study to compare the fusion rates between the nanofuse® bioactive matrix (75%) w/autograft (25%) and autogenous bone in posterolateral gutter spinal fusion.

nanofuse® is indicated to be placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure (i.e. the posterolateral spine and pelvis.) these defects may be surgically created osseous defects created from traumatic injury to the bone. nanofuse® must be used with autograft as a bone graft extender in the posterolateral spine. this product provides a bone graft substitute that remodels into the recipient's skeletal system. radiographic success will be the primary judgement of success. all patient's achieving fused or probably fused status will be judged as a success.

Eligibility criteria:
inclusion criteria: * grade i or ii (less than 50% slip f the cephalic vertebra compared to the caudal vertebra) degenerative spondylolisthesis at one or two contiguous levels between l1 and l5 * lumbar spinal stenosis at the same levels of the degenerative spondylolisthesis producing radiculopathy or neurogenic claudication unresponsive to a minimum of 3 months of nonsurgical treatment, or such patients with worsening neurological condition * patients who are medically suitable for surgical management and the use of nanofuse® bioactive matrix is consistent with product labeling * patients who have consented for surgical treatment * patients able to provide informed consent for the study and complete the questionnaires exclusion criteria: * lytic spondylolisthesis * non degenerative stenosis (example: tumor, trauma, epidural, lipomatosis) * segmental kyphosis at the level of the spondylolisthesis * rheumatoid arthritis * active infection * on long term disability or workers compensation claim

Keywords: demineralized bone matrix primary lumbar fusion autograft lumbar fusion
pilot study of plx3397 in patients with advanced castration-resistant prostate cancer (crpc)

Conditions: Prostate Cancer

Summary: the main objective of this study is to evaluate the effects of plx3397 on male subjects with crpc. secondary objectives include evaluating the safety and tolerability of plx3397 and the anti-tumor effects that plx3397 has on the the subjects.


Eligibility criteria:
inclusion criteria: * histologically confirmed prostate cancer, currently with objective progressive disease. * castrate level of testosterone (\<50 ng/dl). * baseline circulating tumor cell (ctc) count ≥10/7.5 ml blood. * archival tumor tissue (unstained sections, paraffin block, or frozen tumor tissue) has been requisitioned for shipment to the central laboratory. * karnofsky performance status of 80-100. * adequate organ and marrow function. exclusion criteria: * the subject has received: * any systemic chemotherapy (including investigational agents) within 4 weeks (with the exception of nitrosoureas/mitomycin c within 6 weeks), of the first dose of study treatment, or * biological agents (antibodies, immune modulators, cytokines, or vaccines) within 6 weeks of the first dose of study treatment, or * hormonal anticancer therapy (not including lhrh agonists or antagonists) within 2 weeks before the first dose of study treatment. specific restrictions on prior hormonal and other anticancer treatments are detailed in inclusion criterion, or * small-molecular kinase inhibitors or any other type of investigational agent within 4 weeks before the first dose of study treatment or 5 half-lives of the compound or active metabolite, whichever is shorter. * the subject has received drugs used to control loss of bone mass (e.g., bisphosphonates) within 4 weeks prior to the first dose of study treatment. * the subject has symptomatic or uncontrolled brain metastasis or epidural disease requiring current treatment including steroids and anti-convulsants. * the subject has a corrected qt interval calculated by the fridericia formula (qtcf) \>450 ms at screening. * the subject has uncontrolled or significant intercurrent illness including, but not limited to, the following conditions: * cardiovascular disorders such as symptomatic congestive heart failure (chf), \*uncontrolled hypertension * unstable angina pectoris, clinically-significant cardiac arrhythmias * history of stroke (including transient ischemic attack \[tia\] or other ischemic event) within 6 months of study treatment * myocardial infarction within 6 months of study treatment * history of thromboembolic event requiring therapeutic anticoagulation within 6 months of study treatment or main portal vein or vena cava thrombosis or occlusion.

Keywords: crpc prostate cancer bone metastasis advanced castration-resistant prostate cancer (crpc)
descriptive study of the psychological impact of confinement measures in the general population

Conditions: Depression; COVID 19

Summary: quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom. it may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms. from march 17th, 2020 to may 11th 2002, the french government has implemented national containment measures due to the covid-19 epidemic. although there are data on the psychological impact and experience of quarantine measures in people who have been infected or suspected of being carriers of certain pathogens (e.g. ebola), there are no data on such impact in the french population and quarantines lasting longer than 21 days. investigators therefore propose to conduct a human and social sciences study in order to better understand the current situation

the main objective is to describe the psychological state during confinement (and the impact of the confinement) in a sample of the french general population. secondary objectives : * to assess the evolution of psychological health between the period of confinement and post-confinement. * to identify clinical factors modulating psychological state during confinement it is expected to highlight : * a link between the intensity of anxiety symptoms and the number/quality of social contacts * a reduction of anxiety and depression symptoms in the post-confinement period. * higher consumption of drugs during the confinement period self-questionnaires (google form format) are sent by mailing lists or social networks to participants in order to complete the assessment of psychological state. a unique identifier is sent in a separate email. these assessments are performed at least once during the confinement period. it is planned to repeat them when the confinement is lifted: 15 days, 3 and 6 months after the lifting of the confinement because of the risk of developing anxiodepressive symptoms, in particular post-traumatic stressors.

Eligibility criteria:
inclusion criteria: - age\> 18 exclusion criteria: - protective measure (curatorship, guardianship)

Keywords: confinement depression post traumatic stress adults
buprenorphine vs buprenorphine/naloxone on the effects of maternal symptomatology

Conditions: Opioid-use Disorder

Summary: this study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings. this is a randomized controlled trial to a cohort of pregnant women seeking medication-assisted treatment for opioid use disorders. half of participants will receive buprenorphine, while the other half of participants receive a combination of buprenorphine/naloxone

buprenorphine and buprenorphine/naloxone each are used to treat opioid use disorders in pregnancy. buprenorphine has many preferential characteristics over methadone including decreased risk of maternal overdose, lower incidence of preterm labor, less frequent clinical visits, shorter duration of neonatal hospital stay and treatment for neonatal abstinence syndrome. recent studies have found that increasing the dosing frequencies of buprenorphine is more efficacious to prevent maternal withdrawal symptoms, improve compliance, and theoretically produce better pregnancy outcomes. buprenorphine/naloxone, a combination opioid of buprenorphine and naloxone, has also been investigated as an alternative to treatment and maintenance for opioid use disorder. the advantage of the combination of buprenorphine with naloxone is that it reduces the potential for abuse. as a partial mu opioid agonist, buprenorphine alone has the capacity to induce typical opioid effects such as euphoria, which are enhanced when the drug is taken intravenously. by combining buprenorphine with naloxone, an opioid antagonist, the capacity for buprenorphine to be abused is reduced.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * with a confirmed viable intrauterine pregnancy * opioid use disorder * care in a stony brook medicine obgyn clinical office sites * medication-assisted treatment through stony brook medicine obgyn office sites exclusion criteria: * known or suspected allergy to buprenorphine or buprenorphine/naloxone * carrying a fetus with known aneuploidy or anomaly

Keywords: opioid use disorder buprenorphine/naloxone buprenorphine
a prospective observational comparison of smp and eswl for the treatment of renal stones ≥20 mm in children (iau-04)

Conditions: Kidney Stone

Summary: eswl and pnl are the two treatment modalities for kidney stones greater than 20 mm in the pediatric population. eswl is non-invasive, does not require anesthesia and inexpensive, but its success rate may be lower, and require multiple treatment sessions. on the contrary, pnl has a higher success rate, does not require multiple sessions but is an invasive method. compared to standard pnl, miniaturized pnl systems have been shown to decrease complications with comparable success rates. smp is a unique miniaturized pnl system with integrated active irrigation and suction systems. the current literature lacks studies comparing smp and eswl prospectively in the pediatric population. in this study, the effectiveness, reliability, and reusability of eswl and smp will be compared.

to compare the success and complication rates of super-mini-percutaneous nephrolithotomy (smp) and extracorporeal shock wave lithotripsy (eswl) for the treatment of renal stones ≥20 mm in children.an international multicentre, prospective, observational study. pediatric cases with renal stones ≥20 mm who undergo eswl or smp will be evaluated and compared proespectively. the total number of departments planned to be included in the study is 10 and the number of cases is 180.

Eligibility criteria:
inclusion criteria: * children ≤14 years old with renal stones ≥20 mm * willing and able to sign informed consent * normal renal function * no stone-related surgical history * american society of anesthesiology (asa) score 1-2 exclusion criteria: * congenital renal anomalies (horseshoe kidney, ureteropelvic junction obstruction) * uncorrected uti * abnormal coagulation function * morbid obese children (bmi≥35）

Keywords: percutaneous nephrolithotomy pcnl miniperc smp children